Life Science Investing Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF
Life Science Investing Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025
Life Science Investing Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
